

Market Applicability/Effective Date															
Market	FL & FHK	FL MMA	FL LTC	GA	IND	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	NA	NA	X	X	NA	X	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Non-Preferred Inflammatory Bowel Disease Step Therapy

Override(s)	Approval Duration
Step Therapy	1 year

Medications	Quantity Limit
Balsalazide	Preferred
Sulfasalazine	Preferred
Apriso (mesalamine)	Preferred
Asacol HD (mesalamine)	Non-Preferred
Delzicol (mesalamine)	Non-Preferred
Dipentum (olsalazine sodium)	Non-Preferred
Giazo (balsalazide)	Non-Preferred
Lialda (mesalamine)	Non-Preferred
Pentasa (mesalamine)	Non-Preferred

APPROVAL CRITERIA

Requests for a non-preferred inflammatory bowel disease (IBD) agent may be approved if the following criteria are met:

- I. Individual has had a trial of one preferred IBD agent; **OR**
 - II. The preferred IBD agent is not FDA-approved for the prescribed indication; **OR**
 - III. The preferred IBD agent is not acceptable due to concomitant clinical situations, such as but not limited to the following:
 - a. Known hypersensitivity (such as but not limited to, active ingredients, salicylates, sulfonamides); **OR**
 - b. Individual's age;
- OR**
- c. The preferred agent is sulfasalazine and one of the following:
 - i. Individual has a diagnosis of intestinal or urinary obstruction; **OR**

PAGE 1 of 2 12/01/2015

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

WEB-PEC-0415-16 H February 2016

Market Applicability/Effective Date															
Market	FL & FHK	FL MMA	FL LTC	GA	IND	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	NA	NA	X	X	NA	X	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

ii. Individual has a diagnosis of Porphyria;

OR

d. If the non-preferred agent is Pentasa and the individual as a diagnosis of Crohn's Disease (AHFS, DrugPoints B, IIa).

State Specific Mandates		
N/A	N/A	N/A

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2015. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed on: January 11, 2015.

Drug Facts and Comparisons. Facts and Comparisons [database online]. St. Louis, MO: Wolters Kluwer Health, Inc.; 2015. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.